Selux Diagnostics
Steve Lufkin is the current CEO at Selux Diagnostics. Prior to Selux, Steve served as the CEO and Chairman of the Board at Vantix Diagnostics from January 2011 to December 2017. At Vantix, Steve was responsible for setting the strategic direction and overseeing all aspects of the company's business. Steve successfully restructured the organization and launched a global fundraising plan to align capital strategy with business needs.
Before Vantix, Steve was the General Manager at IVAX Diagnostics from January 2010 to December 2010. Prior to IVAX, Steve served as the CEO and Chairman of the Board at DxTech LLC from January 2005 to December 2009.
Steve Lufkin holds a Bachelor's Degree in Health Education from the University of Maine, Orono and a Master of Business Administration (M.B.A.) in Marketing and New Product Development from the Unversity of New Hampshire - Whittemore School of Business and Economics.
Kelly Flentie - Director of Microbiology, Jack Percoskie - CFO, and Aleksandar Vacic - COO, President & Co-Founder report to Steve Lufkin.
Selux Diagnostics
Selux Diagnostics is developing a Next-Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital-acquired infections, and help combat the global antibiotic resistance epidemic.